BUCCOLAM (midazolam): Reviews and patient testimonials
Medication indications
BUCCOLAM 2.5mg, 5mg, 7.5mg and 10 mg oromucosal solution
Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years).
BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have epilepsy.
For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. See section 4.2.
Route of administration: Oral
Molecule: midazolam
Patients' opinions on BUCCOLAM
In brief
General satisfaction level: Be the first to evaluate
Treatment's effectiveness: Be the first to evaluate
Ease of use: Be the first to evaluate
Adherence to prescription: Be the first to evaluate
Detected side effects: Be the first to evaluate
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.